# Corganics

> Corganics is a Dallas-based life sciences company that makes scientifically formulated, physician-advised clinical CBD therapies sold exclusively through licensed healthcare professionals. Its broad-spectrum, THC-free products use Advanced Lipid Technology (A.L.T.) to improve bioavailability and are manufactured in cGMP-compliant, NSF-certified facilities with third-party testing and IRB-approved data. Founded in 2020 by pharmaceutical executives Chad Collins and Reggie Gatewood, the company aims to make CBD a trusted, clinic-grade therapy rather than a retail gamble.

- **Founded:** 2020
- **Headquarters:** Dallas, Texas, United States
- **Founders:** Chad Collins (Co-Founder & CEO), Reggie Gatewood (Co-Founder & President)
- **Team size:** ~19 employees
- **Products:** Corganics Clinical CBD Softgels, Corganics Clinical CBD Drops, Corganics Clinical CBD Cream, Corganics Product Kits (2- and 3-product)
- **Notable:** Rebranded from MD Farma to Corganics and acquired Relief, a natural topical analgesic line., Secured Series A funding led by Altacrest Capital (Dec 2021)., Launched first clinical CBD products to market in 2022.

## Products & services

- **Corganics Clinical CBD Softgels** — Daily broad-spectrum, THC-free softgels made with Advanced Lipid Technology (A.L.T.) for improved bioavailability; 30-count bottles, 900mg/30mg per softgel.
- **Corganics Clinical CBD Drops** — Broad-spectrum, THC-free CBD tincture with cannabinoids, terpenes and flavonoids, formulated with A.L.T. for enhanced absorption; 1400mg per 30ml bottle.
- **Corganics Clinical CBD Cream** — Topical broad-spectrum hemp extract cream blended with vitamin E, aloe vera and other natural ingredients; 250mg, unscented.
- **Corganics Product Kits (2- and 3-product)** — Bundled kits pairing softgels, drops and/or cream for clinician-recommended regimens.

## Achievements

- Rebranded from MD Farma to Corganics and acquired Relief, a natural topical analgesic line.
- Secured Series A funding led by Altacrest Capital (Dec 2021).
- Launched first clinical CBD products to market in 2022.
- Appointed pharmaceutical executive Jeff Hartness to its board of directors.
- Products manufactured in cGMP-compliant, NSF-certified facilities with third-party testing and IRB-approved data.

## Latest updates

- **2022-02** — Appointed pharmaceutical executive Jeff Hartness to the board of directors.
- **2022-01** — Launched first clinical CBD products into the market.
- **2021-12** — Closed Series A funding led by Altacrest Capital; rebranded from MD Farma to Corganics and acquired Relief.

## Links

- Website: https://corganics.com
- LinkedIn: https://www.linkedin.com/company/livecorganics
- Twitter/X: https://twitter.com/CorganicsRelief
- Facebook: https://facebook.com/livecorganics

---

Profile page: https://yespress.io/corganics
Published by YesPress — https://yespress.io
Last updated: 2026-06-16